In this article we review the glucagon like peptide -1 receptor agonist (GLP-1) medications and discuss how to approach using them for weight loss and management in non-diabetic patients.
In this article we review the glucagon like peptide -1 receptor agonist (GLP-1) medications and discuss how to approach using them for weight loss and management in non-diabetic patients.
The United States is facing a growing behavioral health crisis. Now more than ever, novel, safe and effective treatments are needed. Over the past decade, clinical trials of psychedelic-assisted psychotherapies (PAT) have shown promising results for treating a number of common behavioral health conditions with minimal adverse effects. This article provides a brief historical and sociopolitical context surrounding PAT, discusses unanswered questions related to the safety and quality of PAT, and charts a pathway forward through the complex policy, legal, and social barriers to uptake for the state of Missouri in its consideration of PAT as a behavioral health treatment. With careful consideration and proper infrastructure, PAT could represent a paradigm shift in how the field approaches the prevention, treatment, and potential recovery of behavioral health conditions. We outline how Missouri can be at the forefront of advancing the science and practice of PAT - cautiously.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：